Ad is loading...
NTLA
Price
$13.12
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
91 days until earnings call
VCEL
Price
$57.26
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
103 days until earnings call
Ad is loading...

NTLA vs VCEL

Header iconNTLA vs VCEL Comparison
Open Charts NTLA vs VCELBanner chart's image
Intellia Therapeutics
Price$13.12
Change-$0.00 (-0.00%)
Volume$4.48M
CapitalizationN/A
Vericel
Price$57.26
Change-$0.00 (-0.00%)
Volume$335.73K
CapitalizationN/A
NTLA vs VCEL Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NTLA vs. VCEL commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a StrongBuy and VCEL is a Buy.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (NTLA: $13.12 vs. VCEL: $57.26)
Brand notoriety: NTLA and VCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 178% vs. VCEL: 84%
Market capitalization -- NTLA: $1.34B vs. VCEL: $2.8B
NTLA [@Biotechnology] is valued at $1.34B. VCEL’s [@Biotechnology] market capitalization is $2.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $458.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileVCEL’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • VCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, VCEL is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while VCEL’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 5 bearish.
  • VCEL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VCEL is a better buy in the short-term than NTLA.

Price Growth

NTLA (@Biotechnology) experienced а -18.56% price change this week, while VCEL (@Biotechnology) price change was +3.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.72%. For the same industry, the average monthly price growth was -7.79%, and the average quarterly price growth was +1.74%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

VCEL is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-3.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCEL($2.8B) has a higher market cap than NTLA($1.41B). VCEL YTD gains are higher at: 60.798 vs. NTLA (-56.969). VCEL has higher annual earnings (EBITDA): 10.4M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. VCEL (102M). VCEL (97.5M) and NTLA (102M) have identical debt. VCEL has higher revenues than NTLA: VCEL (227M) vs NTLA (43.1M).
NTLAVCELNTLA / VCEL
Capitalization1.41B2.8B50%
EBITDA-527.52M10.4M-5,072%
Gain YTD-56.96960.798-94%
P/E RatioN/A708.88-
Revenue43.1M227M19%
Total Cash658M102M645%
Total Debt102M97.5M105%
FUNDAMENTALS RATINGS
NTLA vs VCEL: Fundamental Ratings
NTLA
VCEL
OUTLOOK RATING
1..100
5918
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
96
Overvalued
PROFIT vs RISK RATING
1..100
9739
SMR RATING
1..100
9788
PRICE GROWTH RATING
1..100
9338
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for VCEL (96) in the Medical Specialties industry. This means that NTLA’s stock grew somewhat faster than VCEL’s over the last 12 months.

VCEL's Profit vs Risk Rating (39) in the Medical Specialties industry is somewhat better than the same rating for NTLA (97) in the Biotechnology industry. This means that VCEL’s stock grew somewhat faster than NTLA’s over the last 12 months.

VCEL's SMR Rating (88) in the Medical Specialties industry is in the same range as NTLA (97) in the Biotechnology industry. This means that VCEL’s stock grew similarly to NTLA’s over the last 12 months.

VCEL's Price Growth Rating (38) in the Medical Specialties industry is somewhat better than the same rating for NTLA (93) in the Biotechnology industry. This means that VCEL’s stock grew somewhat faster than NTLA’s over the last 12 months.

VCEL's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as NTLA (100) in the Biotechnology industry. This means that VCEL’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAVCEL
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 7 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APDYX22.080.10
+0.45%
Artisan Developing World Advisor
JLGPX78.090.03
+0.04%
JPMorgan Large Cap Growth R3
BIBDX12.97N/A
N/A
BlackRock Global Dividend Instl
MUOAX29.84-0.06
-0.20%
Morgan Stanley Instl US Core A
RYELX376.32-1.55
-0.41%
Rydex Electronics A

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-7.15%
VCYT - NTLA
69%
Closely correlated
+0.13%
EDIT - NTLA
68%
Closely correlated
-2.82%
BEAM - NTLA
67%
Closely correlated
-3.16%
CRSP - NTLA
63%
Loosely correlated
+0.62%
PRME - NTLA
58%
Loosely correlated
-5.68%
More

VCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCEL
1D Price
Change %
VCEL100%
+2.56%
VCYT - VCEL
52%
Loosely correlated
+0.13%
BEAM - VCEL
46%
Loosely correlated
-3.16%
NTLA - VCEL
44%
Loosely correlated
-7.15%
SNDX - VCEL
43%
Loosely correlated
+1.14%
EDIT - VCEL
41%
Loosely correlated
-2.82%
More